Flowable Hemostats Market Report 2026

The flowable hemostats market size has grown strongly in recent years. It will grow from $1.02 billion in 2025 to $1.1 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to growth in surgical procedure volumes, increasing adoption of advanced surgical tools, availability of gelatin-based hemostatic agents, expansion of specialty surgical disciplines, improved surgeon awareness of flowable hemostats.

The flowable hemostats market size is expected to see strong growth in the next few years. It will grow to $1.47 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to increasing demand for faster bleeding control, rising focus on patient safety outcomes, expansion of minimally invasive and robotic surgeries, growing innovation in bioresorbable materials, increasing use in emergency and trauma care. Major trends in the forecast period include increasing use of flowable hemostats in complex surgeries, rising adoption of combination hemostatic products, growing demand for rapid hemostasis solutions, expansion of minimally invasive surgical applications, enhanced focus on biocompatible materials.

The increasing number of surgical procedures is expected to drive the growth of the flowable hemostats market in the coming years. This rise in surgical procedures is fueled by an aging population, which increases demand for age-related surgeries, as well as technological advancements that have made surgeries safer and more accessible. Flowable hemostats are particularly valuable in surgeries, as they help control bleeding in areas that are difficult to reach or where traditional methods may be ineffective. For example, in June 2024, a report from the International Society of Aesthetic Plastic Surgery (ISAPS), a US-based professional NGO, indicated that in 2023, the total number of surgical and non-surgical procedures increased by 3.4%, reaching 34.9 million compared to the previous year. Consequently, the growing number of surgical procedures is fueling the flowable hemostats market.

Companies in the flowable hemostats market are focusing on developing advanced hemostatic agents, such as no-swell technology, to meet the evolving demands of modern surgeries. No-swell technology refers to a property of a hemostatic agent that prevents it from absorbing fluids and expanding, making it ideal for use in surgeries where swelling could cause complications. For instance, in January 2023, Medcura Inc., a US-based surgical technology company, received FDA breakthrough device designation for its LifeGel flowable technology, designed to control bleeding in surgical procedures where swelling must be avoided. LifeGel is the first and only flowable hemostatic gel created to address challenges related to hemostatic swelling. The fully hydrated, ready-to-use absorbable agent does not swell, potentially reducing risks such as nerve injury and paralysis. It is cost-effective, retains antimicrobial properties, is relatively transparent, and mucoadheres to tissues, providing a safer and more effective solution for controlling bleeding in complex surgeries.

In May 2025, Merit Medical Systems Inc., a US-based manufacturer of medical devices for interventional, diagnostic, and therapeutic procedures, acquired Biolife Delaware LLC for approximately USD 120 million. Through this acquisition, Merit gained access to Biolife’s proprietary hemostatic product portfolio, including StatSeal and WoundSeal, enhancing Merit’s procedural hemostasis capabilities and supporting the delivery of standardized, reliable bleeding control solutions for vascular access and post-procedure care. Biolife Delaware is a US-based medical device company that develops hemostatic products in powder and disc formats, designed to rapidly seal bleeding at catheter and procedural access sites.

Major companies operating in the flowable hemostats market are Pfizer Inc., Johnson & Johnson Services Inc., Medtronic plc, Medline Industries Inc., Stryker Corporation, Baxter International Inc., B Braun Melsungen AG, Becton Dickinson and Company, Cook Medical Inc., Teleflex Incorporated, Mallinckrodt Pharmaceuticals, Integra LifeSciences Holdings Corporation, Gelita Medical GmbH, Ferrosan Medical Devices A/S, Marine Polymer Technologies Inc, Axio Biosolutions Private Limited, Hemostasis LLC, Aegis Lifesciences Private Limited, Medcura Health Inc, Arch Therapeutics Inc., Starch Medical Inc.

North America was the largest region in the flowable hemostats market in 2025. The regions covered in the flowable hemostats market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the flowable hemostats market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the flowable hemostats market by increasing costs of imported gelatin raw materials, biologic agents, packaging components, and sterile processing equipment used in hemostatic product manufacturing. Hospitals and ambulatory surgery centers in North America and Europe are most affected due to dependence on imported biomedical inputs, while Asia-Pacific faces cost pressures on biologics sourcing. These tariffs are increasing procedural supply costs and procurement budgets. However, they are also encouraging domestic sourcing of biomaterials, localized production of hemostatic agents, and innovation in cost-optimized surgical bleeding control solutions.

The flowable hemostats market research report is one of a series of new reports that provides flowable hemostats market statistics, including flowable hemostats industry global market size, regional shares, competitors with a flowable hemostats market share, detailed flowable hemostats market segments, market trends and opportunities, and any further data you may need to thrive in the flowable hemostats industry. This flowable hemostats market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Flowable hemostats are gelatinous medical devices used to control bleeding during surgical procedures, conforming to irregular wound shapes for precise and effective application. They aid clotting by forming a physical barrier and activating the body’s coagulation cascade, making them particularly suitable for complex or delicate surgical areas.

The main types of flowable hemostat products include active hemostats, passive hemostats, and combination hemostats. Active hemostats are specialized medical agents that actively participate in the blood clotting process, enhancing hemostasis during surgery or in cases of excessive bleeding. These hemostats can be made from various materials, such as porcine gelatin or bovine gelatin, and are used across a wide range of surgical applications, including general surgery, cardiac surgery, vascular surgery, neurosurgery and spine surgery, orthopedic surgery, and more. They are designed to meet the needs of various end users, including hospitals, clinics, and ambulatory surgery centers.

The flowable hemostats market consists of sales of synthetic flowable hemostats, fibrin sealant-based hemostats, and collagen-based flowable hemostats. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.